Until FSD is 99.99% intervention-free and $TSLA assumes liability for injury or damage, investors will add little or no incremental value to TSLA for “supervised FSD.”
Most of us already assume in our earnings forecast and valuation a 10-15% TSLA FSD take rate on current and past delivs: At $99/month adds about $.11/share (~7-8%) to TSLA earnings (past NA owners without FSD 2.0M on 30-day free trials plus current 0.8M NA delivs, both x 15% x $99/month x 12 months x (1 -20% TxRt) / 3.5B shares = $.11/share.
While the following statement should be obvious, I’m taking no chances: If $TSLA cuts the FSD price in half and gets double the take rate, there’s no incremental EPS impact (although more data could lead to greater FSD efficacy which could accelerate Robotaxi progress)$Tesla Motors(TSLA)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
